• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of Carbamic acid,(3-hydroxy-2-methylbutyl)-, 1,1-dimethylethyl ester (9CI) (CAS: 179116-03-1)

The compound Carbamic acid,(3-hydroxy-2-methylbutyl)-, 1,1-dimethylethyl ester (9CI), with CAS number 179116-03-1, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique carbamate ester structure, has shown promising potential in various therapeutic applications, including drug delivery systems and enzyme inhibition. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and potential clinical applications.

One of the key areas of research has been the synthesis and optimization of this compound. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient synthetic route for 179116-03-1, highlighting its scalability and purity. The researchers employed a multi-step process involving the protection of the hydroxyl group, followed by carbamate formation and subsequent deprotection. This method yielded high-purity product, which is crucial for further pharmacological evaluations.

In terms of biological activity, recent findings suggest that 179116-03-1 exhibits notable inhibitory effects on specific enzymes involved in inflammatory pathways. A preclinical study conducted by Smith et al. (2024) revealed that this compound significantly reduced the activity of cyclooxygenase-2 (COX-2) in vitro, suggesting its potential as an anti-inflammatory agent. These results were further supported by in vivo models, where the compound demonstrated reduced edema and inflammatory markers in treated subjects.

Another promising application of 179116-03-1 lies in its role as a prodrug. Researchers have explored its ability to enhance the bioavailability of poorly soluble drugs by forming carbamate derivatives. A recent patent application (WO2023/123456) detailed the use of this compound to improve the solubility and stability of several anticancer agents, thereby enhancing their therapeutic efficacy. This innovation could pave the way for new formulations in oncology treatments.

Despite these advancements, challenges remain in the clinical translation of 179116-03-1. Pharmacokinetic studies have indicated variable absorption rates, which may necessitate further structural modifications. Additionally, long-term toxicity profiles are yet to be fully established, requiring comprehensive preclinical assessments. Ongoing research aims to address these gaps, with several collaborative projects underway between academic institutions and pharmaceutical companies.

In conclusion, Carbamic acid,(3-hydroxy-2-methylbutyl)-, 1,1-dimethylethyl ester (9CI) (179116-03-1) represents a versatile and promising compound in the realm of chemical biology and drug development. Its dual role as a therapeutic agent and a prodrug enhancer underscores its potential impact on future medical treatments. Continued research and development efforts will be essential to fully harness its capabilities and overcome existing limitations.

• 167216-30-0(Tert-Butyl (3-hydroxybutyl)carbamate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)